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Pharmacological targetP2X7 is an intriguing ionotropic receptor for which the activation by extracellular ATP induces rapid inward
cationic currents and intracellular signalling pathways associated with numerous physiological processes such
as the induction of the inﬂammatory cascade, the survival and proliferation of cells. In contrast, long-term stim-
ulation of P2X7 is generally associated with membrane permeabilisation and cell death. Recently, P2X7 has
attracted great attention in the cancerﬁeld, and particularly in the neoplastic transformation and the progression
of solid tumours. A growing number of studies were published; however they often appeared contradictory in
their results and conclusions. As such, the involvement of P2X7 in the oncogenic process remains unclear so
far. The present review aims to discuss the current knowledge and hypotheses on the involvement of the P2X7
receptor in the development and progression of solid tumours, and highlight the different aspects that require
further clariﬁcation in order to decipher whether P2X7 could be considered as a cancer biomarker or as a target
for pharmacological intervention. This article is part of a Special Issue entitled: Membrane channels and
transporters in cancers.
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The purinergic signalling, mediated by multiple receptors called P1
and P2 purinoreceptors upon extracellular stimulation by adenine nu-
cleoside and nucleotide di- or triphosphates respectively, represents
very dynamic and plastic mechanisms for controlling a diversity of cru-
cial biological functions of cells and tissues such as cell-to-cell commu-
nications, secretory activities, membrane excitability, cell proliferation,
cell differentiation and maturation, cell adhesion and migration, and
cell death. P1 and P2 receptors are expressed in a large number of eu-
karyotes and particularly at the plasma membrane of virtually every
mammalian cell [1]. P1 receptors are seven-transmembrane segments
(7TM) G-protein coupled receptors and commonly termed adenosine
receptors because they are physiologically activated by nanomolar
levels of extracellular adenosine. P2 receptors can be divided into two
subfamilies, P2X and P2Y receptors, based on their pharmacology and
the different downstream signalling pathways they are associated
with. The P2Y receptors are also 7TM G-protein coupled receptors, for
which the activating ligands include ATP and some other purine or py-
rimidine di- or tri-phosphate nucleotides such as ADP, UTP or UDP, and
activation initiates signalling pathways dependent on the G-proteins
they are coupled to [2]. There are eight P2Y subtypes in human cells,
which can be further subdivided into two groups; P2Y1, P2Y2, P2Y4,
P2Y6 and P2Y11 are coupled to Gq and activation of these receptors
stimulates the phospholipase C (PLC)-IP3-Ca2+ signalling pathways,
and P2Y12, P2Y13, and P2Y14 are Gi-coupled receptors and their activa-
tion leads to inhibition of adenylyl cyclase (AC). P2Y11 receptor is also
coupled to AC stimulation. [3]. By contrast, P2X receptors are ionotropic
receptors which are physiologically and exclusively activated by extra-
cellular ATP [4]. The P2X receptor family is composed of sevenmembers
with amembrane topology of two-transmembrane segments (TM1 and
TM2) separated by a large extracellular loop for the binding of ATP. P2X
receptors were proposed to be homo- or hetero-trimeric [5]. This has
been conﬁrmed in recent studies performed using X-ray crystallogra-
phy to resolve the three-dimensional structure of the zebraﬁsh P2X4 re-
ceptor [6,7]. P2X receptors constitute functional non-selective cation
channels and their activationmediates very rapid cellular effects, gener-
ally resulting in a depolarizing inward current due to a major inﬂux of
Na+ and Ca2+ into the cytosol at physiological membrane potential,
while aminor but concomitant efﬂux of K+ is generated. Besides this di-
rect effect on the transmembrane polarity, P2X receptors further con-
tribute to important increases in the intracellular Ca2+ concentration
by activation of voltage-gated Ca2+ channels as a result of membrane
depolarisation [8] and therefore activate intracellular Ca2+-dependent
signalling pathways that can have longer-term effects [9], and
there are possibly other signalling pathways following K+ efﬂux [10].
Some P2X receptors have also been identiﬁed in intracellular
compartments, such as the P2X4 which is also localised in the
lysosomes of some cells such asmacrophages,microglia and endothelial
cells [11,12].Having a clear overviewon all the signalling pathways activated, in a
tissue, as a function of time is important to better understand the very
complex resulting biological responses to extracellular ATP exposure.
Indeed, all cells generally express numerous P1 and P2Y receptor
subtypes and many excitable and non-excitable cells are also known
to express P2X receptors. It has to be considered that P2 receptors are
activated in speciﬁc ranges of purines in experimental conditions
when agonists are exogenously applied; some receptors such as P2Y2
receptor and P2X1 receptor are highly sensitive to nanomolar or
submicromolar concentrations of ATP, where some others, like P2X7
receptor, are much less sensitive and need more than 100 micromolar
concentrations to record their activation in vitro [2,5,13]. However,
considering a tissue in physiological conditions, there is no speciﬁc
range of ATP concentration, even a very small one that would only
activate a sole receptor subtype in a particular cell type.
A question naturally arises when one thinks on the purinergic sig-
nalling:what is the biological origin for these nucleotide ligands?Nucle-
otides can be released by cells constitutively or in response to either
mechanical or chemical stimulations. When only considering ATP,
mechanisms for its release into the extracellular compartment are mul-
tiple [14] and can be classiﬁed into i) transmembrane diffusion, ii) vesic-
ular exocytosis and iii) cell lysis-related release. Depending on the
considered release mechanism, extracellular ATP can reach different
concentrations and therefore activates different combinations of P2 re-
ceptors, at least at the initial time. The vesicular release is a physiological
cell-to-cell interaction mechanism that is classically associated with
neurotransmission and leads to the exocytosis of micromolar concen-
trations of ATP in restricted domains and the activation of post-
synaptic and pre-synaptic P2 receptors in close vicinity. However, the
vesicular release of ATP could occur from many non-neuronal cell
types such as endothelial cells [15], urothelial cells [16], ﬁbroblasts
and epithelial lung cancer cells [17], astrocytes [18], osteoblasts [19]
The transmembrane diffusion of ATP through channels, such as
pannexins- or connexins-composed hemichannels, maxi-anion or
volume-regulated anion channels, P2X7 receptors or ATP-Binding Cas-
settes (ABC) transporters, could result in a pericellular halo of low mi-
cromolar ATP concentration that is involved in the regulation of cell
functions via an autocrine and/or paracrine fashion. In comparison,
cell damage is responsible for much higher extracellular concentrations
and the establishment of an ATP gradient possibly activating P2
receptors in multiple cells being in different distances from release
site. Furthermore, ATP can also be synthesised extracellularly by ecto-
adenylate kinases or nucleotide diphosphate kinase [20]. The life time
of extracellular ATP is tightly controlled by multiple ecto-enzymes
such as ectonucleotidases and nucleotide diphosphokinases that con-
vert ATP to ADP and adenosine [21]. The presence and activity of such
ectonucleotidases can terminate ATP-evoked signalling but can initiate
distinctive signalling pathways by the stimulation of ADP-sensitive P2
receptors and adenosine receptors. The adenosinergic pathway plays
an important role in cancer progression since extracellular adenosine
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CD39 andCD73 is immunosuppressive, resulting in tumour progression,
metastases appearance, and poor disease outcomes. Indeed adenosine is
an autocrine or paracrine factor with potent immunoregulatory activity
which facilitates tumour escape from the immune control. Targeted
therapies toward the adenosinergic pathway, such as antibodies recog-
nizing CD73 and CD39, have proven efﬁcacy in mouse tumour models
[22,23]. Therefore, the activation of P2 receptors depends on the con-
centration and identity of nucleotides in the extracellular compartment.
In such conditions it is obvious that extracellular ATP can physiologically
and successively activate numerous receptors and their associated
intracellular signalling pathways. Each of these signalling pathways is
tightly regulated so that cells and tissues evolve homogeneously.
Numerous pathologies appeared to be dependent on the deregulations
of one or multiple elements of the purinergic signalling cascades. One
of these pathologies, which recently has drawn increasing attention, is
the cancer disease, arising from altered purinergic signalling in both
cancerous and non-cancerous cells in the tumour. Several excellent
reviews on this topic were published, some of them being listed here
[24–28].
When focusing on solid tumours, several P2 receptors appear to be
critical in the promotion and/or progression of the cancer [24,25,29]. It
seems clear from numerous studies that some receptors have pro-
cancerous activities and that their pharmacological inhibition, once po-
tent and speciﬁc tools will become available, could represent new op-
portunities to treat the disease. This is certainly the case of the highly
ATP- and UTP-sensitive P2Y2 receptor. There is compelling evidence
to indicate a critical role for this receptor in cancer cell proliferation
[30–32] and resistance to apoptosis [33], thus supporting tumour
growth, and in cancer cell migration [34], invasion [35] and dissemina-
tion, therefore promoting tumour metastasis [36,37]. P2X5, and proba-
bly also P2Y12 receptors, are also strongly expressed by tumour cells
and seem to mediate cell differentiation, resulting in an anti-
proliferative effect in these cells (see [25]).
P2X7 is one of the purinergic receptors which have attracted much
of the attention during the last ﬁve years in the context of cancer
disease. However, while a growing number of studies show the involve-
ment of this particular receptor in the oncogenic process, multiple
aspects remain unclear so far such as the cells in the tumour which
express the P2X7, the conditions for its activation in tumour sites, its
functionality and the cell properties it is regulating. As such,many ques-
tions still remain unanswered that limit consideration of the P2X7 as a
cancer biomarker or as a target for pharmacological intervention. The
present review aims to discuss the current knowledge and hypotheses
on the involvement of P2X7 in the development and progression of
solid tumours, and highlight the different aspects that will have to be
clariﬁed with further investigations.2. ATP in tumour sites
ATP is present in the range of 3–10 mM in intracellular compart-
ments of cells. The extracellular concentration of ATP is much lower. It
was estimated that the physiological concentration of ATP in blood is
in the range of 20–100 nM and is increased after muscular exercise [38]
. However, the concentration of ATP in tissues is hard to measure or es-
timate. The team of Francesco Di Virgilio (Ferrarra, Italy) has developed
a bioluminescent probe, called pmeLUC, for the measurement of extra-
cellular ATP both in vitro and in vivo. This probe is a plasmamembrane
luciferase, with the ATP catalytic site facing the extracellular side, which
can be transfected in reporter cells that are subsequently inoculated into
tissues [39] or directly into cancer cells [40]. This was used to show that
the extracellular microenvironment of tumours contains relatively high
concentrations of ATP, in hundreds of micromolar range, whereas it is
almost undetectable in healthy tissues [41]. While ATP was thought to
be secreted by cancer cells [41,42], it has been postulated that themain source for ATP could be dependent on dying cells [43] such as
those in the perilesional hypoxic regions of solid tumours [44].
While exogenously applied ATP was demonstrated to have anti-
neoplastic effects [45–50], it is also proposed that endogenous extracel-
lular ATP could contribute to cancer progression and promote resistance
to anticancer treatments [25]. Endogenously released extracellular ATP
could also play a beneﬁcial role during anti-cancer therapy by stimulat-
ing the immune system through immunogenic cell death [51]. The ben-
eﬁcial or detrimental role of ATPmay depend on themechanisms of cell
death, on the type of ATP release, on the concentrations of ATP and ob-
viously on the purinergic receptor signalling pathways involved. ATP
can derive from different compartments of the cell, coming from mito-
chondria, endoplasmic reticulum or cytoplasm [52]. Tumour cells can
undergo different types of cell death with both passive release or active
secretion of ATP. Several mechanisms of ATP secretion in dying, dead or
stressed cells have been reported [53]. Different programmed cell
deaths such as apoptosis, autophagic cell death and pyroptosis promote
ATP release by dying cells. Moreover, the non-programmed cell death
called necrosis also leads to ATP release. These fourways to die promote
ATP release via differentmechanisms, and can be beneﬁcialwith immu-
nogenic properties or detrimental with increased proliferation and/or
migration of tumour cells. Anti-cancer therapies may reorient these
beneﬁcial versus detrimental potential of ATP release. In particular,
the use of immunogenic cell death inducers such as chemotherapy
agents in cancer therapy or infection by oncolytic viruses may favour
immunogenic cell death. Indeed, oncolytic viruses were shown to in-
duce secretion of ATP from human cancer cells [54]. Extracellular ATP,
besides acting as a danger-associated molecular pattern (DAMP) that
can stimulate anti-tumour immunity, also functions as a “ﬁnd me”
signal through P2Y2 receptors, facilitating rapid attraction of antigen
presenting cells to sites of extensive apoptotic cell death.
2.1. Necrosis
ATPmay be released by dying cells in response to non-programmed
cues, such as the necrosis produced by pressure disruption, hypoxic in-
jury, toxins, cancer, infection and trauma. Necrosis is characterised by
cellular swelling and rupture of the plasma contents [55]. These pro-
cesses activate the innate immune system and can promote a strong
sterile inﬂammation through the NLRP3 inﬂammasome that activates
caspase-1 leading to the secretion of the mature pro-inﬂammatory
cytokine interleukin (IL)-1β and IL-18. This activation may be triggered
in part by ATP produced by mitochondria and released from damaged
cells [56].
2.2. Apoptosis and autophagy
Cells which die as part of physiological responses, such as apoptotic
or autophagic cells, are removed from tissues to prevent immune reac-
tions and maintain tissue homeostasis. Although apoptotic cell death
has been considered to be non-immunogenic, recent studies unravelled
that several anti-neoplastic agents and irradiations can trigger immuno-
genic apoptosis in particular through the active secretion of ATP [57].
Moreover, cells dying via autophagy can trigger pro-inﬂammatory
responses through the release of ATP driving the inﬂammasome activa-
tion [40,51,58]. Indeed, autophagy has a dual role: it is a survival mech-
anism responding to poor nutritional or stress conditions to avoid cell
death (and suppress apoptosis) by degradation of long-lived proteins
and damaged organelles [59,60]. However, under certain circumstances,
autophagy constitutes an alternative way for cell to dye through the
autophago-lysosomal pathway [58]. Autophagic cell death induced by
nutrient deprivation, hypoxia and infectious pathogens is a non-lytic
process, with cell budding and characterised by caspase-independent
autophagosome formation and action of lysosomal proteases. The
DAMPs released are ATP and the nuclear protein chromatin-binding
high mobility group box 1 protein (HMGB1). Phagocytosis of human
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theNLRP3 inﬂammasome and secretion ofmature IL-1β in humanmac-
rophages via an ATP-dependent mechanism [61]. Blockade of K+ efﬂux
during phagocytosis, addition of P2X7 antagonist, incubation in the
presence of apyrase, or silencing NLRP3 protein expression, inhibit IL-
1β secretion response [61]. Moreover, in mouse, the NLRP3
inﬂammasomewas activated aftermacrophage engulfment of autopha-
gic dying cells [62]. In autophagic dying cells, ATP was released via
pannexin-1 channels. Moreover, in phagocytosis of autophagic dying
cells, both P2X7 activation and subsequent K+ efﬂux in macrophages
are obligatory steps for inﬂammasome activation [62]. A recent report
from G. Kroemer's group has shown that in response to immunological
cell death inducers, ATP redistributes from lysosomes to autolysosomes
and is secreted by a mechanism that requires the lysosomal protein
LAMP1, which translocates to the plasma membrane in a strictly
caspase-dependent manner. These ﬁndings suggest that caspase- and
pannexin-1 channel-dependent lysosomal exocytosis has an essential
role in ATP release in immunological cell death triggered by immuno-
genic chemotherapy [63]. In vivo, chemotherapeutic agents induce
tumour autophagic cell death which is immunogenic through recruit-
ment of dendritic cells and T cells into the tumour via the secretion
[40,51,61].
In conclusion, it appears particularly important to understand the
factors that determine the beneﬁcial or pathogenic responses to extra-
cellular ATP on cancer evolution. Extracellular ATP concentrations
might be a determinant of the ﬁnal outcome. Indeed it was shown
that 250 nM extracellular ATP, which activates P2Y receptor signalling,
does not modulate T regulatory cells, whereas 1 mM ATP which more
likely activates P2X7, stimulates T regulatory cells, enhancing their abil-
ity to proliferate and to be immunosuppressive [64]. In addition,
prolonged release of low amounts of ATP diminishes the capacity ofma-
ture dendritic cells to initiate type 1 immune responses [65,66].
3. Functional particularities of the P2X7 receptor and relevance to
the cancer disease
Among themembers of the P2X receptors family, the P2X7 receptor
[67,68] is very unique bymultiple features, from itsmolecular structure,
to its biophysical and pharmacological properties [69]. Even the cells
and tissues expressing P2X7 in physiological conditions are different
from those observed for other P2X. Indeed, P2X1–P2X6 receptors are
expressed widely, even if not exclusively, in the nervous system [70]
where they underlie the neurotransmission at post-synaptic sites gen-
erating action potentials or at pre-synaptic sites modulating neuro-
transmitter release [9]. In contrast, while the expression of P2X7
receptors in glial cells is well accepted [71,72], its expression in neurons
remains a topic of debate because of the use of poorly selective antibod-
ies [73,74]. The well accepted distribution of P2X7 receptor is in
immune cells coming from the hematopoeitic lineage, such as mono-
cytes, macrophages, dendritic cells, B and T lymphocytes, mast cells
and epidermal Langerhans cells, in which participation of the receptor
in the immune response has been extensively documented. Particularly,
the participation of P2X7 is critical in the inﬂammation by inducing the
activation of the inﬂammasome and caspase-1 with the subsequent re-
lease of the pro-inﬂammatory IL-1β from Pathogens Associated Molec-
ular Patterns (PAMPs)-primed macrophages and microglial cells [75,
76]. The P2X7 receptor is expressed in bone cells, in both osteoblasts
[77,78] and osteoclasts [79], and seems to be critical in the balance
maintained between osteoblast and osteoclast activities in normal
bone [80] as well as deregulations occurring in bone-related cancers
[81]. Furthermore, P2X7 is expressed in some epithelial cells, and espe-
cially from exocrine glands. Its expression in submandibular gland acini
and ducts, as well as its involvement in the salivary secretion in rodents
is well documented [82,83]. P2X7 is also expressed in kidney cells [84],
and speciﬁcally in basolateral membranes [85], however its physiologi-
cal role remains elusive. Taken together, these different studies suggestthat P2X7 receptors seem to be mainly involved in the response to ex-
tracellular ATP in non-excitable cells.
As introduced, P2X7 also demonstrates structural, such as the
carboxy-terminal end, and functional properties, such as the sensitivity
to ATP or the membrane permeabilisation for cationic dyes induced by
its stimulation, that are very unique among all P2X. Some of these func-
tional particularities have been considered as being hallmarks of the
P2X7 receptor, and were often used to characterise P2X7 expression
or functionality in native cells or in heterologous expression systems.
More than being solely hallmarks, we believe that they could be of bio-
logical relevance, and particularly in the context of the cancer progres-
sion. Furthermore the gene encoding for P2X7 is highly polymorphic
and give many splice variants exhibiting both structural and functional
particularities. These aspects are commented in the following sections.
3.1. Gene, splicing variants and single nucleotide polymorphisms (SNPs)
The human P2X7 is encoded by the P2RX7 (purinergic receptor P2X,
ligand-gated ion channel, 7) gene located on the locus 12q24.31. The
P2RX7 gene comprises 13 coding exons. Ten naturally occurring alterna-
tive splicing variants have been identiﬁed in humans and have been
named P2X7A to J [86,87]. The P2X7A variant is the well-characterised
full-length receptor [68]. Among the ten, ﬁve splice variants (P2X7B,
P2X7C, P2X7E, P2X7G and P2X7J) are lacking the C-terminal intracellu-
lar tail of the receptor. The truncated P2X7B seems to display the same
pharmacological properties, towards both agonists and antagonists, as
the P2X7A and to be functional as an ion channel but it is unable to trig-
ger membrane permeabilisation for large cationic molecules [86], a
property referred to as being the pore formation and often associated
with cell apoptosis. The P2X7I variant is due to a 5′-intronic splice site
and is responsible for a null allele, that is ineffective in inducing mem-
brane permeabilisation to ﬂuorescent dyes such as ethidium [88].
The P2X7J variant is a polypeptide composed of 258 amino acid res-
idues and compared to the full-length variant it lacks the distal 337
amino acids that correspond to the entire intracellular carboxyterminal
end, the second transmembrane domain and the distal part of the extra-
cellular loop. This variant, which is unable to induce pore formation, has
been proposed to oligomerise with the full-length P2X7A receptor and
to act as in dominant negative fashion [87]. This variant was identiﬁed
in cervical cancer cells and was proposed to represent a new marker
for cervical cancer or of defective apoptosis by preventing the cell
death due to the stimulation of P2X7A by the ATP analogue 3′-O-(4-
benzoyl)benzoyl-ATP (BzATP) [89].
Splice variants have also been identiﬁed in rodents. The ﬁrst identi-
ﬁed was termed P2X7k and is results from using alternative exon 1 in
the rodent P2XR7 gene. This variant is fully functional and bears a differ-
ent N-terminal extremity and ﬁrst transmembrane domain conferring
an increased sensitivity to agonists, and slower deactivation kinetics
compared to the human variants [90]. There are also two variants,
P2X7 13B and P2X7 13C, that are truncated in the C-terminus, due to
an alternative splicing in the exon 13. These two variants displayed a
low membrane addressing, low channel function and no membrane
permeabilisation [91].
Therefore, depending on the splice variants considered the biophys-
ical properties of the receptor, its surface expression, as well as
interacting molecules and downstream signalling pathways could be
highly different, and this might be of importance in the cancer.
The human P2X7 receptor is highly polymorphic, and numerous sin-
gle nucleotide polymorphisms (SNPs) have been identiﬁed in the last
years. While a vast majority of these SNPs are located into intronic
sequences, about 150 non-synonymous SNPs (NS-SNPs) have been re-
ported. Some of these variants have drawn a lot of attention and were
particularly studied following genetic association studies that proposed
them as important genetic factors altering the susceptibility of individ-
uals to various diseases [92,93]. Some of these NS-SNPs are responsible
for alterations in functional properties of the human receptor, which
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The V76A, R117W, L191P, T357S, E496A or G150R, E186K, R276H,
R307Q, I568N polymorphisms are responsible for partial or complete
loss-of-function receptors, respectively, while the mutations H155Y,
H270R and A348T are responsible for gain-of-functions [94–100].
Many of these polymorphismswere postulated to be involved in the
aetiology of different pathologies [92], however, only the 1513A N C
polymorphism (rs3751143), resulting in the loss-of-function E496A
substitutionwas further studied in the context of the cancerous disease.
It was initially proposed to be associated with familial B-cell chronic
lymphocytic leukaemia (CLL) and to contribute to the pathology by
inhibiting the P2X7-dependent apoptotic signalling pathway [101,
102]. Authors of these studies found that the 1513C allele frequency
was signiﬁcantly higher in familial CLL patients than in patients with
sporadic CLL or in normal subjects coming from the Australian popula-
tion [102] and proposed that the presence of this polymorphism could
have a prognostic signiﬁcance. However, such an association has not
been supported by subsequent studies performed in Swedish [103] or
British cohorts [104,105], and no correlationwas found between the ex-
istence of this polymorphism in the P2RX7 gene in CLL patients and their
clinical outcome, characterised by the time between the ﬁrst diagnosis
of the disease and the initiation of chemotherapy [106]. Besides, the fre-
quency of this polymorphism studied in samples coming from patients
with multiple myeloma was not signiﬁcantly different from that found
in normal healthy subjects. There was no effect of the 1513A N C poly-
morphism on the clinical prognostic markers and survival in multiple
myeloma [107].
Only two studies were performed to study the prevalence of SNPs in
the P2X7 gene in solid tumours. Theﬁrst onewasperformed in papillary
thyroid cancer (PTC) in which the expression of two P2X7 polymor-
phisms was analyzed in lymphocytes from 121 patients. While the
heterozygous expression of the 1513A N C polymorphism was not sig-
niﬁcantly different in the PTC patient group versus healthy subjects, it
was found a very strong increase of the homozygous expression in
patients suffering from the follicular histological variant of PTC. In detail,
13.6% of patients with follicular PTC were homozygous for the 1513C
polymorphism comparedwith 2.6% of patients with the classical variant
of PTC and 2% of healthy subjects. Furthermore, a positive correlation
was identiﬁed between the 1513A N C polymorphism and TNM stage
and overall tumour aggressiveness [108]. This would suggest that a
loss-of-function of the receptor could be favourable for cancer
progression.
The second study was very recently performed in the context of
prostate cancer, and led to an opposite hypothesis. Indeed a genetic
analysis was performed in the P2X7 gene for studying well
characterised SNPs, and it was found a signiﬁcant association of the
1513A N C polymorphism leading to a loss-of-function of the receptor
in low grades of prostate cancerswhile themajor allele seemed to be as-
sociated with aggressive stages [109].
3.2. General structure of the P2X7 receptor
The P2X7 receptor, like other P2X, is functional under a multimeric
assembly of three subunits [110,111]. Each subunit bears a dolphin-
like three-dimensional topology as predicted by the X-ray crystallogra-
phy analyses performed on the zebraﬁsh P2X4 receptor in the closed
and ATP-bound open states [6,7] and subsequent structural modelling
[69]. In line with other P2X, the P2X7 subunit consists of a large, glyco-
sylated and cysteine-rich extracellular domain composed of 285 amino
acids, two transmembrane-spanning helices called TM1 and TM2
domains, a short intracellular N-terminal domain and an intracellular
C-terminal domain. The TM1 and TM2 domains in the human P2X7
comprise residues T28-S47 and N332-L354, respectively. One structural
particularity of P2X7, being responsible for multiple functional speciﬁc-
ities, is the fact that with 595 amino acid residues the P2X7 protein is
signiﬁcantly bigger than any other P2X subunit. This difference in theprotein size is solely due to the C-terminal domain which is longer
than those of all other P2X subunits by containing from 70 to 220
more residues [5].
The C-terminus of P2X7 has been implicated in regulating receptor
function and sub-cellular localisation, but also in protein–protein inter-
actions and the initiation of intracellular signalling cascades [112]. Of
importance, it was demonstrated that the P2X7 C-terminus possesses
a microdomain (P582-Y595) containing a canonical motif Yxxϕ
(Y588-S589-G590-F591). This motif was critical for the receptor
targeting to basolateral membranes of epithelial cells, and that its dele-
tion or mutations of key amino acid residues induced the targeting to
the apical membrane [85]. Since P2X7B and P2X7J variants are truncat-
ed in the C-terminus, they are devoid of this basolateral motif, and
changes in their speciﬁc expression in epithelial cancer cells could inter-
ferewith epithelial cell physiology and could be responsible or associat-
ed with neoplastic transformation.
3.3. Sensitivity to ATP and allosteric modulation of P2X7
While themammalian P2X7 orthologs exhibit important differences
in their agonist sensitivity, the rat P2X7 being 3–10-fold and 30–100-
fold more sensitive to ATP and BzATP, respectively, than the human
[68,113] andmouse receptors [114], they all constitute the less sensitive
P2 receptors to extracellular ATP. Residues and motifs involved in P2X7
sensitivity to both ATP and BzATP in the different mammalian orthologs
were recently reviewed [69]. Experimentally, when acutely activated by
exogenous ATP, hundreds of micromolars are required to record P2X7-
mediated currents, Ca2+ increases or P2X7-related dye uptake [5] and
there are only few biological conditions for which such high concentra-
tions can be reached, the more likely being due to the local release of
ATP content by dying cells or when ectonucleotidases are down-
regulated [115]. Thus P2X7 was thought to mostly be activated in
threatening situations such as infections and tissue injuries.
However, it has been proposed that P2X7 could also be allosterically
modulated in different manners. In such conditions, the receptor could
display a higher sensitivity and could potentially be activated in vivo
in lower concentrations of ATP in the extracellular compartment. As
an example, the mouse P2X7 can be activated by extracellular nicotin-
amide adenine dinucleotide (NAD). This activation of the receptor can
be independent of, or in synergy with, ATP binding via ADP-
ribosylation of the residue R125, catalyzed by the activity of ADP-
ribosyltransferase 2 ecto-enzymes [116,117]. Residue R125 is proposed
to be located in close vicinity with the putative ATP-binding site and
ADP-ribosylation would favour the binding of the ADP moiety to this
site and thereby activate the receptor [117]. The corresponding residue
in the human P2X7 is also predicted to project towards the ATP-binding
site supporting the hypothesis that ADP-ribose binds to the same site as
ATP [118].
The antimicrobial peptide LL-37 coming from the maturation of
cathelicidin hCAP18, the only cathelicidin found in humans, was also
postulated to activate the P2X7 receptor through a mechanism that is
not fully understood. Indeed, LL-37 was initially demonstrated to pro-
mote the processing and release of IL-1β from monocytes [119] and to
prevent the apoptosis of neutrophils through the activation of P2X7
[120]. Later on, it was shown that LL-37 could activate human P2X7 re-
ceptors, as assessed as P2X7-dependent dye uptake and intracellular
calcium increase, heterologously expressed in HEK293 cells and native
receptors expressed in murine NIH3T3 ﬁbroblasts and this way leading
to an increase in cell proliferation [121]. Importantly, LL-37 exhibits a
helix-forming propensity due to the speciﬁc distribution of positively
and negatively charged residues allowing for the formation of intramo-
lecular salt bridges [122]. Thanks to this helicoidal structure, LL-37 is
postulated to insert deeply into, and to affect eukaryotic membrane in-
tegrity [123]. It was therefore suggested that the aggregation of LL-37 in
the plasmamembrane may be involved in the activation of P2X7 [121].
Interestingly, it has been shown that while LL-37 is present at the
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mRNA and proteins in different tumours such as breast, lung, prostate,
ovary cancers and melanoma. Furthermore, it seems that it is synthe-
sised by cancer cells and not by stromal cells, and that its expression is
signiﬁcantly higher in biopsies of high than in low histological grades
of tumours [124–128]. LL-37was shown to increasemetastatic develop-
ment in immunodeﬁcient SCID mice inoculated with human cancer
cells [129]. Conversely, LL-37 could participate in the activation of im-
mune cells and thereby the anticancerous response of the organism
[130,131]. These different properties have been postulated to be under
the regulation of P2X7 receptors (see Section 5), either expressed by
cancer or immune cells of the tumours. Thus, it can be postulated that
LL-37 exerts its cancerous effects through the allosteric modulation of
P2X7 receptors. Alternatively, it is possible that other allosteric modula-
tors from the tumourmicroenvironment, not yet identiﬁed, could act on
P2X7 to increase its sensitivity to ATP in vivo.
3.4. P2X7 receptor function: ion channel and pore dilatation
3.4.1. P2X7 receptor ion channel properties
Activation of P2X7, like all other members of the P2X receptor fam-
ily, opens within milliseconds a transmembrane ion-conducting path-
way that is selectively permeable to small cations such Ca2+, Na+ and
K+ [67,68]. As mentioned above, opening of the P2X7 receptor ion
channel can mediate extracellular Ca2+ entry into the cell to elevate
the intracellular Ca2+ concentrations, and also intracellular K+ efﬂux
or movement out of the cell. For ligand-gated Ca2+-permeable ion
channels like the P2X receptors including the P2X7, the ion channel
functional properties can be studied using the patch-clamp recording
technique to directly measure agonist-induced ionic currents through
open channels (e.g., [113]). An alternative and widely-used means is
using ﬂuorescent Ca2+ indicators, such as Fura-2 or Fluo-4, to monitor
agonist-induced increases in the intracellular Ca2+ concentrations
resulting from extracellular Ca2+ inﬂux and thereby indirectly charac-
terise the Ca2+-permeable ion channel functions (e.g., [132]). The ion
channel properties of P2X7 have several biophysical properties that
contrast with the other P2X receptors. A unique functional property of
the P2X7 receptor ion channels is that they display no or little
desensitisation in the presence of agonist even for several tens of
seconds or minutes, in contrast with the complete desensitisation of
the P2X1 and P2X3 receptors within a few seconds and the strong
desensitisation of P2X2, P2X4 and P2X5 receptors during tens of sec-
onds [5,132]. Also, the P2X7 receptor ion channels exhibit no discernible
rectiﬁcation, that is, the open channels permit ions to move into or out
of the cell with similar easiness (e.g., [133]).
The most striking particularity of P2X7-mediated currents, com-
pared to all other members of the P2X family [5] and to all other
ligand-gated ionotropic receptors, is the absence of current
desensitisation to agonist application. Instead, P2X7-mediated currents
are incredibly increasing in amplitude upon repeated brief applications
or sustained application of agonists, and this is associated with an in-
crease in the sensitivity to the agonist and was called facilitation
[133–135]. As detailed previously, a structural particularity of P2X7
compared to all other P2X members, is the existence of a 200
residues-long intracellular carboxyterminal end that is involved in
both receptor functional regulations, by post-translational modiﬁca-
tions, cellular localisation and protein interactions, and signalling path-
way activation [112]. From the initial studies describing P2X7, it was
demonstrated that the C-terminus was critical in regulating gating
properties [67,68]. The offset (deactivation) kinetics of P2X7-mediated
currents were also known, from the initial characterisation of the recep-
tor, to be dependent on the C-terminus and to differ from rat to human
orthologs [68]. It was also known for long that the P2X7 was the only
P2X receptor to show such incredible current amplitude and onset ki-
netics increases during both prolonged and repeated agonist stimula-
tions [67,68,136]. These increases in current amplitudes and activationkinetics are also accompanied by an increase in the agonist sensitivity
during the facilitation process [135]. However, insights into the molec-
ular mechanism supporting such biophysical properties appeared
quite recently and remain so far incomplete. It was demonstrated that
the rat P2X7 presented both Ca2+-dependent and Ca2+-independent
facilitation processes. Indeed the Ca2+-dependent facilitation was due
to the binding of Ca2+-calmodulin (CaM) to a 17-residues-long 1-5-16
calmodulin bindingmotif between I541 and R557. Such amotif is differ-
ent from thewell-known “IQ” or “IQ-like”motifs as it is characterised as
being Ca2+-dependent, meaning that CaM needs to coordinate four
Ca2+ ions at each of its EF-hands, before to bind to the motif. The com-
bined substitutions I541T and S552C in the C-terminus of the rat P2X7
resulted in the complete loss of CaM binding to the receptor and the
Ca2+-dependent facilitation, without affecting the Ca2+-independent
facilitation or the increase in agonist sensitivity [135]. Interestingly,
only the rat receptor, among all mammalian and non-mammalian
P2X7 cloned up to now, seems to bear such a CaM-binding site. Indeed,
the human receptorwas shown to only possess an important current fa-
cilitation process that was Ca2+-independent. However, when
substituting three residues of the human C-terminus, T541I, C552S
and G559V, a CaM-binding motif and a Ca2+-dependent facilitation,
similar to what is observed with the rat receptor, were introduced.
This indicates that the change in human receptor conformation, follow-
ing Ca2+-CaM binding and responsible for the increase in current
amplitude, was also possible [134]. The molecular process responsible
for the Ca2+-independent facilitation is still unknown but seems to be
independent on the receptor addressing to the membrane. However,
another domain of the C-terminus, close to the TM2 and composed of
18 amino acids (from C372 to V389) and containing 6 cysteine residues,
was described to be determinant. This cysteine-rich domain is highly
conserved between species, and its deletion in the rat sequence resulted
into the complete loss of facilitation. This mutant also showed higher
agonist sensitivity and slower deactivation kinetics compared to the
WT receptor [134]. Thus, it is speculated that the increase in agonist sen-
sitivity during current facilitation is correlated to the Ca2+-independent
process, found in all orthologs. It could also be postulated that this
cystein-rich domain acts as a hinge region for the control of conforma-
tional changes of the receptor during both Ca2+-dependent and Ca2+-
independent facilitation. This same region was also demonstrated to
be critical in receptor dilatation and permeability to N-methyl-D-
glucamine (NMDG), but not in the dye uptake [137]. A separate study
describes such increased current responses as sensitisation, and
proposes that it results from the difference in the conductive state of
the ion channel arising from the different number of ATP molecules
bound to the P2X7 receptor [138].
While the molecular mechanisms involved in P2X7 facilitation/sen-
sitisation are not fully characterised, such a process, along with the ab-
sence of desensitisation, must be taken into account when thinking on
the biological functions of P2X7 in vivo. Indeed, this could explain an ac-
tivity of the receptor in vivo under low but constant concentrations of
extracellular ATP that could be released through an autocrine/paracrine
mechanism, and not only it would maintain but exacerbate plasma
membrane depolarisation and signalling pathways dependent on
P2X7 activation.
3.4.2. P2X7 receptor activation-induced pore formation
P2X7 is perhaps best known for its capacity to induce a phenomenon
called membrane permeabilisation that refers to the formation of large
pores that allow passage of large cationic molecules up to 900 Da across
the plasma membrane [67,68]. Due to this unique functional property,
this receptor was initially named P2Z receptor to separate from other
P2X receptors before molecular cloning [139]. The large pores appear
after the activation of P2X7 for tens of seconds to minutes. The time-
course or kinetics of the large pore formation or dilation can be deter-
mined using patch-clamp recording in bi-ionic extracellular and intra-
cellular solutions; upon prolonged application of agonist, there is a
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ganic cations, such as NMDG [67,68,137], which are much larger in size
than the physiological cations such as Ca2+, Na+ and K+. The large pore
formation can be demonstrated undermore physiological conditions by
monitoring progressive efﬂux of preloaded ﬂuorescent dyes, for exam-
ple, calceine [140], and more commonly, accumulation of extracellular
ﬂuorescent dyes, such as YO-PRO-1 (e.g., [141]) and ethidium
(e.g., [98]), inside the cells during receptor activation. The latter is wide-
ly referred to as ﬂuorescent dye uptake.
Two fundamentally distinctive pore-forming mechanisms have
been proposed to explain how the large pore forms following P2X7 re-
ceptor activation [5]. The ﬁrst and widely recognisedmechanism is that
separate protein(s) constitute the NMDG-permeable or dye uptake
pores and the pores open upon activation of P2X7 via physical interac-
tions or conformational coupling. There is evidence to support the
hemichannel composed of pannexin-1 proteins as being the pore-
forming unit [140,142–144]. The second mechanism entails that the
large pore is an intrinsic functional property of the P2X7 receptor,
resulting from progressive dilatation of the small ion-conducting path-
way. Such a mechanism offers single and satisfactory interpretations
of the remarkable effects on the large pore-forming capacity and dy-
namics induced by diverse structural difference or disturbances [67,
90,145,146]. This is also supported by a recent study showing that
P2X7 receptor ion channels carrying mutations in the ion-conducting
pathway are able to pass molecules with sizes up to 14 Å [133]. There-
fore, both mechanisms have gained strong support by various studies
so far. It is worth pointing out that these mechanisms are mutually ex-
clusive and in fact, a multiple of pore-forming mechanisms have been
proposed [147]. It is also worth mentioning that formation of large
pores occurs after activation of some other homomeric or heteromeric
P2X receptors, including P2X2, P2X4, P2X2/3 and P2X2/5 [148–150]
and via different pore-forming mechanisms. For example, there is evi-
dence to suggest no major role of pannexin-1 channel in the pore for-
mation induced by activation of the recombinant P2X2 receptor in
HEK293 cells [151] or endogenous P2X4 receptor in microglia [152].
3.5. P2X7 pharmacology and ligands: potential cancer therapeutic
strategies?
The ﬁrst three mammalian P2X7 receptors were molecularly identi-
ﬁed in 1996–1997 [67,68,136]. Compelling evidence emerged from
subsequent studies using transgenic P2X7 deﬁcient mice and derived
cells supports an important role for the P2X7 receptor in mediating
ATP-induced generation of IL-1β, a key proinﬂammatory cytokine, and
in the pathogenesis of arthritis and chronic pain [153–155]. These
ﬁndings prompted huge interest in search for potent and selective
P2X7 receptor ligands. ATP and BzATP still remain the agonists available
up to date. As mentioned above, BzATP, an ATP synthetic analogue, ex-
hibits a greater potency at the P2X7 receptor than ATPwith an opposite
order of potency at the other P2X receptors [13]; such a unique agonist
proﬁle has been widely used to indicate functional expression of P2X7
receptors, but both ATP and BzATP are not useful therapeutic agents,
because of their rapid degradation by ubiquitously expressed and
membrane-delimited enzymes, such as ecto-nucleoside triphosphate
diphosphohydrolases. In contrast, several potent P2X7 antagonists
have been discovered over the past decade, some of which show strik-
ing selectivity among P2X7 receptors of different mammalian species
[69]. KN-62, initially identiﬁed as a Calmodulin-kinase II inhibitor
[156], was also characterised as being the ﬁrst potent human P2X7 se-
lective antagonist versus other P2X receptors with an IC50 of
40–100 nM, to which the rat P2X7 receptor is largely insensitive [157].
Brilliant blue G (BBG) is the ﬁrst potent rat P2X7 selective antagonist
with an IC50 of 10 nM, which is slightly less potent at the P2X7 receptor
of other species origins [158]. Systemic administration of BBG in rodents
reduced tissue loss and improved motor function following spinal cord
injury [159], and prevented development of morphine tolerance [160],suggesting that pharmacological intervention of P2X7 receptor is a
promising therapeutic approach. A number of medicinal chemistry
programmes have led to discovery of several series of drug-like
compounds with distinctive structural properties as highly selective
human P2X7 antagonists with nanomolar potency. Representative
examples shown in Fig. 1 include A438079 and A83997 (tetrazole
or trizole-based compounds); A740003, A759029 and A804598
(cyanoguanidine derivatives); AZ10606120 (an adamantane amide);
AZ11645373 (a cyclic imide); and CE-224535 (an azauracil derivative).
As discussed above, prolonged activation of P2X7 receptors causes
cell death and there is some evidence suggesting such a cytolytic effect
may bring therapeutic beneﬁts to certain cancerous conditions such as
human hematopoietic malignancies including chronic lymphocytic leu-
kaemia (CLL) [161]. Heterologous expression in K562 cells of theN187D
mutant P2X7 receptor, identiﬁed in human J6-1 leukaemia cells,
accelerated cell proliferation and reduced BzATP-induced cell death
[162]. Moreover, the tumours developed faster, with the size and
weight becoming larger and heavier, in immune-deﬁcient mice im-
planted with cells expressing the mutant receptor. These observations
suggest enhancing P2X7 receptor activity may slow down the patho-
genesis and progression of CLL and thus be beneﬁcial.
Our recent studies, on the other hand, have shown that selective in-
hibition using KN-62 and A740003 of the human P2X7 receptor endog-
enously expressed in the highly invasive breast cancer MDA-MB-435 s
cells and human lung cancer A549 cells prohibited ATP-induced cell mi-
gration and particularly cell invasiveness in vitro and in vivo [132,163].
In addition to synthetic chemicals developed by medicinal chemistry,
active compounds from traditional remedies prepared using plants
and other natural sources could be used in therapies. For example, em-
odin (1,3,8-trihydroxy-6-methylanthraquinone) is an anthraquinone
derivative, extracted from the rhubarb Rheum ofﬁcinale Baill that has
been used in Chinese traditional medicine for centuries, and is known
to exhibit antitumour properties as well as anti-inﬂammatory and im-
munosuppressive properties, albeit the underlying mechanisms
appearing multiple [132,164–166]. Our initial study showed that emo-
din is a potent P2X7 antagonist, inhibiting ATP-induced macrophage
cell death [167]. In the following study, we have further demonstrated
that emodin suppressed the invasiveness of breast MDA-MB-435 s
and lung A549 cancer cells through antagonism of the human P2X7 re-
ceptor [132]. These studies provide clear evidences to indicate an im-
portant role for the P2X7 receptors in mediating cancer cell
metastasis, the major cause for high mortality. These studies also
showedproof of concept that pharmacological inhibition of the P2X7 re-
ceptors as a promising therapeutic strategy. P2X7 antagonists have been
tested in clinical trials for treatment of rheumatoid arthritis, osteoarthri-
tis, chronic obstructive pulmonary disease and inﬂammatory bowel dis-
ease. It is clear that it becomes interesting to test in pre-clinical studies
and clinical trials P2X7 antagonists, which have proved to be clinically
safe such as CE-224535 and emodin, in treatment of some epithelial
cancers, such as breast cancer.
4. Expression and functional properties of P2X7 receptors in solid
tumours
In most types of cells endogenously or heterogeneously expressing
P2X7, the pharmacological activation of the receptor using high concen-
trations of ATP or BzATPwas generally associatedwith dramatic cellular
events such as membrane permeabilisation and blebbing, loss of asym-
metric distribution in phosphatidyl serine, cell swelling, increase of in-
ternal Ca2+, loss of mitochondrial potential [168,169]. These entire
phenomena were demonstrated to be reversible when the agonist ap-
plications were brief, and were associated to what was called
“pseudoapoptosis”. However, these events were eventually leading to
cell death upon a prolonged stimulation (more than 30 min) [169].
This latter aspect was reminiscent to the initial properties associated
with the cytolytic function of extracellular ATP due to this same receptor
Fig. 1. Chemical structures of representative small molecular weight P2X7 receptor selective antagonists developed frommedicine chemistry. (A), tetrazole/trizole-based compounds A-
438079 and A-83997. (B), cyanoguanidine derivatives A-740003, A-759029 and A-804598. (C), adamantane amide AZ10606120. (D), cyclic imide AZ11645373. (E), azauracil derivative
CE-224535. The concentration inhibiting by 50% agonist-induced human P2X7 receptor responses (increases in the cytosolic Ca2+, ionic currents or ﬂuorescent dye uptake) or IC50 value is
shown in brackets.
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that P2X7 over-expression could be deleterious for cells [67,169,174,
175] and that stimulating its activity could represent new clinical ther-
apies for treating cancers [50].
During the last decade, multiple studies assessed the expression
levels of P2X7 in different cancer biopsies and cancer cell lines (See
Table 1). P2X7 expression seemed to be decreased in some studies
while others reported a very high increase of mRNA, proteins, or both
in several tumours compared to corresponding normal tissues. Howev-
er, the full functional characterisation of the receptor was very often
questioned and rarely provided, thus limiting the hypotheses on its par-
ticipation in oncogenic processes.
4.1. Expression levels in solid tumours and association with tumour grade/
tumour progression
4.1.1. Breast cancer
There are contradictory results in assessing the expression of P2X7
in both biopsies and cell lines. An initial study on breast cancer was per-
formed to identify the protein expression of P2X7 by immunohisto-
chemistry (IHC) on 40 haematoxylin and eosin (H&E) stained samples
of different histological categories including normal, hyperplastic tis-
sues as well as lobular carcinoma in situ, ductal carcinoma in situ, inva-
sive lobular and invasive ductal carcinoma [176]. Normal and
hyperplastic breast epithelial samples were completely devoid of P2X7
expression, while all studied cases of in situ or invasive lobular or ductal
carcinoma were intensely labelled. However, only cancer cells from in-
vasive carcinomas had membrane labelling of P2X7, while cancer cells
from in situ carcinoma seemed to only show intracellular immunoreac-
tivity. While this initial study was very important, it was not speciﬁedwhat molecular part of the receptor was used as an antigen for the an-
tibody used. As such it is not clearwhether the IHC signal obtained is re-
ferring to one ormultiple P2X7 variants, and particularly if this antibody
was also recognizing the C-terminus truncated variants. Although the
functionality of P2X7 was not assessed in invasive carcinomas, authors
were still under the inﬂuence of the cytolytic hypothesis on the cellular
role of the receptor. They postulated that “an attempt was being made
to induce apoptosis” [176], suggesting in a deterministic evolutionary
conception, that following the carcinogenetic transformation cancer
cells have initiated the apoptotic process, but unsuccessfully. However,
authors proposed that P2X7 expression could be used in order to iden-
tify and differentiate early stages of breast cancers from hyperplastic
lobules [176].
Correlatively to the initial IHC, some studies proposed that P2X7
could be over-expressed during the breast cancer initiation or progres-
sion and become functional at the plasmamembrane of cancer cells. In-
deed, the expression of bothmRNAand proteins for P2X7was identiﬁed
in the highly invasive human breast cancer cell lines MDA-MB-435s,
while it was very weakly or not expressed in non-cancerous mammary
epithelial cells HMEC, MCF-10A and 184A1 [132,163]. Furthermore,
P2X7 was found to be fully functional at the plasma membrane of
MDA-MB-435 s cells, giving rise to ATP-induced inward currents, in-
creases in intracellular calcium concentrations ([Ca2+]i) and ethidium
uptake, that were prevented by antagonists of P2X7 or by speciﬁc
small interfering RNA [132,163]. It was indicated that the variant
expressed was the full length P2X7A. However, the expression of
other variantswasnot addressed. In linewith this hypothesis, P2X7pro-
teins were also detected in highly invasive MDA-MB-231 breast cancer
cells [177]. In weakly invasive MCF-7 cancer cells, messengers RNA
were ampliﬁed and while proteins could be detected in Western
Table 1
P2X7 expression, functionality and postulated roles in solid tumours.
Expression of P2X7 mRNA was assessed by PCR, and P2X7 proteins by immunohistochemistry (IHC), western blotting (WB) or Flow cytometry (FC).
Cancer types Samples: biopsies/cells
(h, human; m, mouse; r, rat)
Expression (mRNA, proteins,
variants)
Functionality of P2X7 at
the plasma membrane
Cellular effects of P2X7
agonist/antagonists
Postulated role References
Breast cancer Human biopsies of in
situ or invasive
lobular or ductal breast
carcinoma
Protein (IHC) Not assessed – Early marker [176]
Human lobular or ductal
breast
carcinoma
Protein (IHC) Not assessed – Apoptosis [178]
MDA-MB-435 s (h) mRNA, proteins (WB), P2X7A. Current, [Ca2+]i, dye
(WB), P2X7A.
Yes (ATP/KN62,
A438079, A740003,
emodin)
Cancer cell
migration and
invasiveness
[132,163]
MDA-MB-231 (h) Proteins (WB) Not assessed Not assessed Apoptosis [179]
Proteins (WB) Not assessed Yes (BzATP /−) Invasion [177]
mRNA, protein (WB) Not assessed Yes (ATPγS/oATP) Inhibition of migration and
growth
[219]
MCF7 (h) mRNA No current Not identiﬁed Not identiﬁed [34]
Proteins, variant? Not assessed Not assessed Apoptosis [179]
Py8119 (m) mRNA Not assessed Yes (ATPγS /−) Inhibition of migration and
tumour growth
[219]
Breast cancer Human cancer biopsies Protein (IHC) Not assessed – Early marker [180]
[181]
Laser-capture microdissected
biopsies
mRNA, proteins (IHC, WB) Not assessed – Cancer marker [182]
PC-3 (h) mRNA, proteins (WB) Not assessed Not assessed Not identiﬁed [212]
PC-3 (h), DU-145(h) – Not assessed Yes (ATP/KN-62) Cancer cell invasiveness [109]
PC-3(h) mRNA No lucifer yellow
uptake
Yes (ATP/−) Not identiﬁed [241]
Lung cancer A549 (h), PC-9(h), H292 (h) mRNA, protein (WB) Ethidium uptake Yes (ATP, BzATP/A438079, emodin) Cancer cell migration
and invasiveness
[132,183,184]
Pancreatic cancer Human biopsies mRNA, protein (IHC) Not assessed Not assessed Not identiﬁed [185]
Papilliary thyroid cancer
(PTC)
Human PTC biopsies mRNA, protein (IHC, WB) Not assessed – Trophic activity
through IL-6 release
[186]
FB1 (h), FB2 (h) Protein (IHC) [Ca2+]i Not assessed Cancer aggressiveness [186]
Human PTC biopsies Protein (IHC) Not assessed (ATP, BzATP/oATP, KN-62) Poor prognosis [188]
Human PTC biopsies Full-length protein (IHC) Not assessed – – [189]
Human PTC biopsies Not assessed – [178]
Skin cancers Nonnmelanoma
Necrotic/aptotic areas of basal
cell and suqmous cell carcinomas
Protein (IHC) Not assessed – Apoptosis [190]
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A431 (h) Protein (IHC) Not assessed Yes (ATP, ATPγS, BzATP) Apoptosis [190]
Melanoma
Human biopsies Protein (IHC) Not assessed – Apoptosis [191]
Human biopsies Protein (IHC), P2X7A? Not assessed – Apoptosis [30]
A375 (h) mRNA, protein (IHC), P2X7A? YO-PRO-1 uptake Yes (BzATP/KN-62) Apoptosis [30]
Skmel28 (h), Bris (h), HBL
(h), 518A2 (h)
mRNA Not assessed Not assessed Not identiﬁed Fig. 2, this
review
B16 (m) mRNA, protein (WB) Ethidium uptake Yes (ATP/A438079, oATP) m [192]
[204]
B16 (m) mRNA, P2X7a variant Ethidium uptake Yes (ATP/−) Cell death [193]
B16 (m) mRNA, protein (WB) Not assessed Yes (ATP,BzATP / KN-62) Apoptosis [218]
Brain cancers Neuroblastoma
Human biopsies Protein (IHC), P2X7A? – – – [42]
GI-CA-N (h), HTLA-230 (h), GI-ME-
N
(h), LAN-5 (h), LAN-1 (h), SK-N-BE-
2
(h) and SH-SY-5Y (h)
Protein (IHC), P2X7A? Not assessed Not assessed – [42]
ACN (h) Protein (IHC), P2X7A? [Ca2+]i, YO-PRO-1
uptake
Yes (ATP, BzATP / KN-62) Substance P-dependent
proliferation
[42]
Neuro-2a (m) mRNA, protein (WB) [Ca2+]i Yes (ATP / oATP, BBG, A438079) Cell survival [205]
Neuro-2a (m) mRNA, protein (WB, IHC) Current, [Ca2+]i Yes (ATP, BzATP /KN-62, BBG,
A438079)
Undifferentiated proliferative
phenotype
[206]
Glioma
C6 (r) mRNA, protein (WB, IHC) [Ca2+]i, ethidium
uptake
Yes (BzATP/oATP) Migration [195]
C6 (r) mRNA, protein (WB, IHC) [Ca2+]i Yes (BzATP/oATP) Suppression of P2X7 promotes
gowth through EGFR induction
[196]
GL261 (m) mRNA, protein (WB) Propidium iodine
uptake
Yes (ATP, BzATP / oATP) Cell death [197]
U-138MG (h), U-251MG (h) mRNA, protein (FC) Ethidium uptake Yes (ATP, BzATP / A740003) Not identiﬁed [194]
M059J (h) mRNA, protein (FC) Ethidium uptake Yes (ATP, BzATP / A740003) Increase in radiosensitive cell
death
[194]
Colorectal cancers Human colon adenocarcinoma Protein (IHC) Not assessed Not assessed Not identiﬁed [178]
HCT8 (h), Caco-2 (h) mRNA, protein (WB, IHC) [Ca2+]i Yes (ATP, BzATP / oATP) Apoptosis [178]
MCA38 (m) mRNA, P2X7a variant Ethidium uptake Yes (ATP, BzATP / KN-62) Cell death [193]
CRC MC-26 (m) mRNA, proteins Not assessed Not assessed – [199]
Uterine cancers Cervix and endometrial
cancer biopsies
Reduced expression of mRNA, proteins (WB,
IHC)
– – – [178,201,202]
Cervical biopsies, CaSki (h), HeLa
(h), SiHa (h), HT3 (h)
Dominant-negative P2X7J Not assessed Not assessed protection against apoptosis [87,89]
Ovarian cancer Human ovarian biopsies Protein (IHC) – – Cell survival [200]
SKOV-3 (h), CAOV-3 (h) Protein (IHC) [Ca2+]i Yes (ATP, BzATP / A438079,
AZ10606120)
Cell survival [200]
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tions of ATP was ineffective in inducing P2X7-related inward currents
suggesting that the receptor could not be functional at the plasmamem-
brane [34].
In contrast with these studies, an IHC study performed with 26
breast carcinoma samples, 13 ductal carcinomas and 3 lobular carcino-
mas indicated a tendency for a reduced expression of the full-length
P2X7 in cancer biopsies [178]. Another recent study examined the pro-
tein expression of P2X7 by IHC, using an antibody recognizing the
carboxyterminal end of the receptor, in 80 paired-samples breast biop-
sies and found that P2X7 immunostainingwas reduced in cancer tissues
compared to adjacent non tumour mammary tissues [179]. In the same
study, P2X7 proteins were however identiﬁed in both weakly MCF-7
and highly aggressive MDA-MB-231 cancer cells, but its expression
was proposed to be reduced, similarly as in cancer biopsies, by the over-
expression of the mature oncogene miRNA miR-150 [179].
4.1.2. Prostate cancer
An initial study of a cohort of 116 biopsies, obtained frommen aged
from 47 to 86 years, and conﬁrmed to be cancerous in the range of the
Gleason sum score 4–9, assessed the expression of P2X7 proteins by
IHC [180]. It was found that all cancer biopsies were positive for P2X7
expression, with no correlation with the age of patients or with the
Gleason score. P2X7 was also identiﬁed in non-cancerous epithelial
cells adjacent to the margins of the tumour; however the labelling
seemed to be distinct depending on the stage/vicinity of cells to the
tumours. Indeed P2X7 appeared to be expressed in the nucleus of
non-cancerous cells, then into the cytoplasm and ﬁnally on the apical
membrane of cells progressing into the cancer phenotype. In compari-
son, P2X7was totally absent fromprostate tissues coming frompatients
with no evidence of cancer. These results raised the possibility that
P2X7 appears during the cancerous progression [180]. In a subsequent
study, the same team assessed by IHC the expression of P2X7 and com-
pared this to levels of the prostate-speciﬁc antigen (PSA) in prostate
cancer biopsies from 174 patients. They found a positive correlation
between the P2X7 expression and increasing levels of PSA in patients
who were later on diagnosed to be cancerous by H&E staining. These
results further sustained the hypothesis by which the expression of
P2X7 could represent an early marker for the diagnosis of prostate
cancer [181]. In these two initial studies, it is not clear whether the
P2X7 variant expressed is the full-length P2X7A or another alternative
splicing variant, and its functionality was not assessed.While it is possi-
ble that P2X7 is functional at the plasma membrane of prostate cancer
cells, the authors still characterised the receptor as being “apoptotic”
and suggested that it might be non-functional.
Ravenna and collaborators assessed the mRNA and protein expres-
sion of different markers generally associated with inﬂammation, in
both cancer and non-cancer prostate samples coming from laser-
capturemicrodissection of biopsies and showingnoor low leukocyte in-
ﬁltrate. They found that P2X7 was highly up-regulated in cancer cells
compared to non–cancer cells from the adjacent host tissue and that
this was correlated to the over-expression of cancer proliferative recep-
tors Epidermal Growth Factor Receptor (EGFR) and Estrogen Receptor
(ER)α. Authors suggested that a whole pattern of proteins usually asso-
ciated with inﬂammatory or reparative functions are up-regulated in
cancer cells of transformed tissues, devoid of detectable leukocyte inﬁl-
trate, and could contribute to the cancer progression [182].
4.1.3. Lung cancer
To date there is no paper assessing the expression of P2X7 in cancer
versus non-cancer lung biopsies with the aim of studying possible cor-
relations with cancer progression and clinical grades. However, there
are several in vitro studies relating the expression of P2X7 in human
lung cancer cells, such as in A549, PC-9 and H292 but not in non-
cancerous BEAS-2B bronchial epithelial cells [132,183,184], suggestingthat P2X7 could be up-regulated during the malignant transformation
of lung epithelial cells.
4.1.4. Pancreatic cancer
The mRNA expression of P2X7 and the presence of proteins were
analysed in chronic pancreatitis (samples from 11 patients) and pancre-
atic cancer (samples from 28 patients) and compared to normal pancre-
as tissues. P2X7 was signiﬁcantly up-regulated at the mRNA level in
biopsies of chronic pancreatitis compared to normal pancreas and to
pancreatic cancer. At the protein level, P2X7 was not signiﬁcantly in-
creased in both pancreatic cancer and chronic pancreatitis biopsies
compared to normal pancreas. In conclusion, P2X7was not signiﬁcantly
overexpressed in pancreatic cancer, and seemed to bemainly expressed
by inﬁltrating leukocytes in the pancreas [185].
4.1.5. Papillary Thyroid Cancer (PTC)
In an initial study performed on the thyroid cancer, the mRNA for
P2X7 was found to be about two times more abundant in 37 human
papillary thyroid cancer samples when compared with contralateral
non-cancer tissues. Furthermore, immunochemistry was also per-
formed with anti-P2X7 antibodies and P2X7 proteins were shown to
be strongly expressed in all cancerous tissues tested, both in classical
and in follicular histological forms of the cancer, while they were not
present in normal thyroid tissue of the same individual. Malignant
thyrocytes showed a diffuse P2X7 labelling into the cytoplasm as well
as intense labelling at the cell periphery. P2X7 mRNA and functional
proteins were also expressed in FB1 and FB2 human thyroid cancer
cell lines in which stimulation by both ATP and BzATP enhanced the re-
lease of the IL-6 [186]. IL-6 local expression is related to the aggressive-
ness of PTC [187] and P2X7 could therefore participate in the
development of such a cancer phenotype. The over-expression of the
full-length P2X7 in PTC was conﬁrmed in another IHC study performed
with 4 samples [178]. In a subsequent IHC study performedwith 43 PTC
samples compared to 19 samples coming from nodular goiter, it has
been demonstrated that the expression of both the X-linked inhibitor
of apoptosis (XIAP) and the P2X7 was increased in PTC samples. Fur-
thermore, P2X7 expression was associated with an increased in the tu-
mour size as well as with capsular inﬁltration and lymph node
metastases. Authors of the study proposed that P2X7 may represent a
predictor of the aggressiveness of PTC [188]. Recently, P2X7 protein ex-
pressionwas studied by IHC in 170 biopsies of PTC patients, 84 of which
having the chronic autoimmune thyroid diseaseHashimoto's thyroiditis
(HT) and the other 86 without HT. The expression of P2X7 was signiﬁ-
cantly higher in the absence of HT and correlated with poor prognostic
factors such as tumour multifocality, lymphovascular invasion and
extra-thyroid extension [189]. In conclusion, P2X7 seems to be over-
expressed in PTC and associated with the aggressiveness of the disease.
4.1.6. Skin cancers
Skin cancers are histologically subdivided into non-melanomas,
which comprise basal cell and squamous-cell carcinomas, and melano-
mas. Squamous cell carcinomas are more frequent andmore aggressive
than basal cell carcinomas since they can give rise to distant metastases.
Melanoma is the more dangerous and aggressive skin cancer, which
initiates after the cancerous transformation of melanocytes and has a
high potential for metastasis.
4.1.6.1. Basal-cell and squamous-cell carcinomas. The expression of P2
receptors was assessed by IHC analysis in human biopsies of basal cell
and squamous cell carcinomas, and P2X7 was found to be expressed,
especially in the necrotic center of nodular basal cell carcinomas and
in apoptotic cells in superﬁcial multifocal and inﬁltrative basal cell car-
cinomas. P2X7 is also expressed in the human A431 squamous cell car-
cinoma cell line [190] and,while its functionalitywas not demonstrated,
stimulation with high doses of ATP, ATPγS and BzATP reduced cell
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was involved in the ATP-mediated apoptosis in cancer cells.
4.1.6.2. Melanoma. In an IHC study performed on 80 biopsies coming
from patients with superﬁcial spreading melanomas, the P2X7 protein
was reported to be over-expressed in cancer versus non-cancer sam-
ples. This increase in P2X7 labelling was also extended to 2 μm layer
of non-cancerous keratinocytes of the epidermis surrounding the tu-
mour [191]. Another study performed in 14 specimens of humanmela-
nomawith an antibody recognizing a C-terminal epitope in P2X7, came
to conﬁrm these initial results. Indeed, it showed that all melanoma
samples expressed P2X7, and over 75% of cancer cells in the biopsy
were stained positively [30]. Again, these results could suggest that
P2X7 is over-expressed during the neoplastic transformation of
keratinocytes. Authors of these two separate studies indicated P2X7 as
a potential melanoma marker. The receptor was associated with apo-
ptosis [30] and was even proposed that “melanoma cell proliferation
overwhelmed the apoptotic defence” [191].
Data obtained from our group indicated that mRNA expression of
P2X7, among other P2X, can be detected by RT-PCR in Skmel28, Bris,
HBL, 518A2 human melanoma cell lines (Fig. 2). The presence of pro-
teins and their activity at the plasma membrane was not assessed so
far. P2X7 mRNA and proteins were also identiﬁed in human melanoma
cell lines such as the A375 [30], and in the murine B16 melanoma cell
line [192] in which the variant expressed is P2X7a and not the P2X7k
variant [193] that exhibits a higher ligand sensitivity [90].
4.1.7. Brain cancers
4.1.7.1. Neuroblastoma. Neuroblastomas are malignant tumours of the
childhood that mainly originate from embryonic nerve cells in the sym-
pathetic nervous system. In 2006, it was shown, by IHC using an anti-
body targeting the last 20 amino acids of the receptor, that P2X7
proteins were expressed in neuroblastoma primary tumours. The vast
majority of cancer cells in the tumour displayed an intense labelling.
The number of the samples analyzed was moderate but the majority
of tumours showed high P2X7 expression irrespectively of the histolog-
ical grade of the disease (localised versus metastatic). P2X7 proteins
were also detected in the cytosol of numerous human neuroblastomaP2X1 P2X2 P2X3 P2X4 P2X5 P2X6 P2X7
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Fig. 2. Expression proﬁle of P2 receptors in human melanoma cancer cell lines. Represen-
tative RT-PCR experiments analysing the expression of mRNA for all the P2X receptors,
and showing the expression of P2X7 in Skmel28, Bris, HBL and 518A2 melanoma cells.
Cells were grown in Dulbecco's modiﬁed Eagle's medium (DMEM), supplemented with
10% foetal calf serum. Reverse transcription-PCR experiments were done using standard
protocols and PCR primers indicated in our previouspublication [119]. Brieﬂy, the temper-
ature proﬁle for PCR was 4 min at 94 °C followed by ampliﬁcation for 40 cycles, each
consisting of 1 min at 94 °C, 30 s at 60 °C, and 1 min at 72 °C and a ﬁnal extension for
2 min at 72 °C. PCR products were analyzed by electrophoresis in 1.8%-agarose gels
containing ethidium bromide, and visualised by UV trans-illumination.cell lines such as ACN, GI-CA-N, HTLA-230, GI-ME-N, LAN-5, LAN-1,
SK-N-BE-2 and SH-SY-5Y, and at the plasma membrane of at least
ACN cells [42]. Even though more characterisations are needed, it can
be nonetheless postulated that this immunostaining is representative
of the expression of a non-C-terminus truncated variant, such as the
P2X7A.
4.1.7.2. Glioma. Gliomas are malignant primary tumours of the central
nervous system, deeply inﬁltrating adjacent tissues in the brain, and pa-
tients bearing these tumours have a very poor prognosis. The principal
therapy actually used for the management of disease is the surgical
resection of the tumour, and there are attempts in improving the efﬁca-
cy of other treatments such as radiotherapy by manipulating the
purinergic signalling. In this context there are several in vitro experi-
ments that have been performed in either human or rat glioma cell
lines. As such P2X7 is expressed, in mRNA and proteins, in human
U-138MG, U-251MG and M059J, in rat C6 and in mouse GL261 glioma
cells [194–197]. To date, there is no study comparing the levels of
P2X7 in human glioma versus non-glioma samples.
4.1.8. Colorectal cancers
In an IHC study performedwith a limited number of human samples,
full-length P2X7 immunoreactivitywas identiﬁed in the basolateral side
of the normal epithelium, while in colon adenocarcinoma, the immuno-
reactivity was distributed throughout the cells. In all the ﬁve cases stud-
ied, P2X7 levels were similar between cancer cells and normal cells
[178]. P2X7 was also identiﬁed in human HCT8, Caco-2 and murine
MCA38 (P2X7a but not k variant) and CRC MC-26 colorectal cancer
cell lines [193,198,199].
4.1.9. Ovarian cancer
In a recent study, P2X7 proteins were identiﬁed by IHC to be in sim-
ilar levels in biopsies fromnon-cancerous and cancerous humanovarian
biopsies [200]. This study also showed functional expression of P2X7 at
the plasma membrane of SKOV-3 and CAOV-3 ovarian carcinoma cells
[200].
4.1.10. Uterine cancers
Uterine cancers certainly represent the cancer types for which there
is the less ambiguity so far. Indeed, multiple publications, coming from
the team of G. Gorodeski, demonstrated that mRNA and proteins for
the full-length P2X7 were expressed in epithelial cells of normal uteri
such as endometrial, endocervical and ectocervical tissues, and was re-
duced in cervical squamous cell carcinomas as well as in endometrial
and endocervical adenocarcinomas. Furthermore, there was a reduced
expression of P2X7 in hyperplastic pre-cancerous endometrium com-
pared to normal endometrium. These observations have led the authors
to propose that P2X7 expression could be used as a biomarker for uter-
ine epithelial cancers [178,201,202]. The reduction in the P2X7 expres-
sion was claimed to result from the over-expression of micro RNAmiR-
186 andmiR-150 in cancer cells [203]. Furthermore, the dominant neg-
ative P2X7J variant truncated in the C-terminus, was identiﬁed in cervi-
cal and normal cancer cells. The expression levels of P2X7J were very
similar in normal and cancer cells, but the expression of P2X7A was
higher in normal cells. Authors proposed this P2X7J variant to represent
a newmarker for cervical cancer or of defective apoptosis by imposing a
dominant negative inhibitory effect on P2X7A and thereby preventing
the cell death due to the stimulation of P2X7A by BzATP [87,89].
5. Role of P2X7 receptors in determining tumorigenesis
5.1. P2X7 receptors in cancer cells
As indicated in the previous section, P2X7 is often found to be
expressed in cancer biopsies and cancer cells, and multiple studies
have assessed the cellular properties related to cancer progression or
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ever, depending on the cell types or theways bywhich P2X7were stud-
ied, the results appeared to strikingly different and sometimes
apparently opposite indicating that P2X7 could be pro-cancerous or
even anti-cancerous. A detailed analysis of the method used could be
informative to highlight apparent discrepancies.
5.1.1. Pro-cancerous activities of P2X7 in cancer cells
5.1.1.1. Promoting cell survival, proliferation and tumour growth. In mu-
rine melanoma B16 cells, P2X7 was found to be responsible for the ex-
tracellular release of ATP in acidic conditions (pH 6.4) mimicking the
acidosis found in the core of solid tumour as a result of the hypoxia.
This release resulting in extracellular ATP in the 10 nM range, which
wasprevented bypharmacological antagonismusingA438079 or by ex-
pressional repression of P2X7 using small interfering RNA (siRNA), was
responsible for an increase in cancer cell proliferation in vitro. The in-
crease in cell proliferation was due to another purinoreceptor than the
P2X7, which remains to be identiﬁed [192]. Therefore P2X7 was indi-
rectly promoting cancer cell proliferation, by releasing extracellular
ATP, and its pharmacological inhibition using oxidised-ATP (oATP) sig-
niﬁcantly inhibited the tumour growth of B16-bearing syngenic mice
[192]. γ-radiations (0.5 Gy) were also proposed to induce ATP release
by the same melanoma cells partially through P2X7 [204].
A P2X7 variant not truncated in its C-terminus, and possibly the
P2X7A, is expressed in human neuroblastoma biopsy samples and in
numerous neuroblastoma cell lines. In ACN cells the receptor is
expressed at the plasma membrane and is thought to be functional.
ATP and/or BzATP stimulations induced increases in the [Ca2+]i, plasma
membrane depolarisation and YO-PRO-1 uptake. This latter parameter
was prevented by incubation with KN-62 [42]. ATP stimulation also
caused cell rounding, membrane blebbing and the release of vesicles
into the extracellular space, without activation of caspase-3. P2X7
activation was associated to cancer cell growth through the paracrine
release of the trophic substance P from nucleotide-activated neuroblas-
toma cells. Further evidence supporting the role of P2X7 in controlling
cell survival and proliferation of neuroblastoma cells was shown that
the treatment of mouse neuroblastoma Neuro-2a cells with the ATP
hydrolase apyrase or with P2X7 antagonists, oATP or BBG, decreased
cancer cell viability and cell number. Conversely, the pharmacological
inhibition of P2X7 in these cells promoted neurite outgrowth and
neuronal differentiation of cells [205,206]. One could hypothesise that
P2X7 activity in neuroblastoma cells maintains an undifferentiated
and proliferative phenotype that could be representative of cancer cell
characteristics and cancer stem cells properties.
P2X7 is expressed at the plasma membrane of SKOV-3 and CAOV-3
ovarian carcinoma cells. In these cells, BzATP stimulation increased the
[Ca2+]i and the levels of phosphorylated Akt (pAkt) and ERK (pERK),
which were prevented by the use of A438079. BzATP did not induced
cell death in these two cell lines. The mechanical stimulation of cells
produced by a ﬂow of physiological solution was responsible for an in-
crease in the [Ca2+]i that was abolished in the presence of apyrase,
therefore suggesting release of ATP. Furthermore, the incubation of
cells with apyrase, with the P2X7 antagonist AZ10606120, or their
transfectionwith the P2X7E496Amutant inducing a dominant negative
effect on the wild-type receptor, reduced cell viability by about 30%.
Taken together these results led the authors to suggest that basal
activity of P2X7, induced through the auto-release of ATP, increased
pERK and pAkt levels and maintained cell viability [200].
With a series of excellent studies, Adinolﬁ and Di Virgilio and collab-
orators demonstrated that P2X7 displays a trophic activity in the
absence of pharmacological exogenous activation [207]. They have pro-
posed the idea that P2X7 could support different cellular aspects that
are critical to the oncogenic transformation, to cancer cell proliferation
and tumour growth through a basal activity of the receptor. They initially
demonstrated that the transfection of Human Embryonic Kidney(HEK293) cells with the full-length human P2X7, having the capacity to
induce membrane permeabilisation, increased the resting mitochondrial
potential, the basal mitochondrial Ca2+ concentration and the intracellu-
lar ATP content, and thus enhanced to whole mitochondrial activity
which increased cell proliferation and conferred to the cells the ability
to grow in the absence of serum. These effects were dependent on an au-
tocrine/paracrine tonic stimulation by released ATP, as they were
abolished in the presence of apyrase. On the other hand, the sustained
stimulation of P2X7 by exogenous ATP had opposite effects and resulted
in cell death [208]. Later on, using the same cellular model, they demon-
strated that P2X7 transfection increased the ability of the endoplasmic
reticulum to accumulate, store, and release Ca2+. Furthermore, P2X7
expressing cells survived and proliferated in serum-free conditions and
were resistant to apoptosis triggered by ceramide, staurosporin, or intra-
cellular Zn2+ chelation. The nuclear factor of activated T cells complex 1
(NFATc1)was strongly activated in the P2X7 transfectants in the absence
of exogenous agonist. All these effects were abrogated in presence of
oATP or apyrase, further supporting the initial ﬁnding that P2X7, under
tonic conditions in response to basal ATP release, had an anti-apoptotic
activity or even promoted cell growth [209]. The P2X7B variant retaining
its ion channel activity but unable to inducemembrane permeabilisation,
had similar effects, and cells over-expressing this variant showed the
ability to inﬁltrate into soft agar, like tumour cells would do. The co-
expression of the full-length P2X7A with the P2X7B induced the forma-
tion of heterotrimers that potentiated all the cellular effects observed in
the presence of P2X7B alone (i.e. increased intracellular Ca2+ and Ca2+
release from the ER, potentiation of NFATc1 activation, increased cell sur-
vival and inﬁltrating colonies) and increased the intracellular contents of
ATP as well as the release of ATP [146]. They further demonstrated that
the expression of P2X7 promoted tumour growth in vivo. HEK293 cells
expressing P2X7 exhibited amore tumorigenic and anaplastic phenotype
than control cells in vivo when inoculated subcutaneously into nude
mice. The growth of these tumours was reduced by intratumoral injec-
tion of oATP. P2X7-expressing tumours secreted high amounts of VEGF
and showed a more developed vascular network than control tumours.
This tumoral growth and neoangiogenesis of P2X7-expressing tumours
were blocked by intratumoral injection of the VEGF-blocking antibody
Avastin (bevacizumab), aswell as the pharmacologic ormolecular inhibi-
tion of P2X7. Similar results were obtained using mouse CT26 colon
carcinoma cells transfected with mouse P2X7 receptor inoculated into
syngenic immunocompetent BALB/c mice. Tumour growth was also
inhibited by the blockade of P2X7 endogenously expressed in B16
mousemelanoma and in ACNhumanneuroblastoma cells and inoculated
to syngenic C57Bl/6 or nude mice, respectively [210].
5.1.1.2. Induction of pro-invasive properties. In the rat C6 glioma cell,
mRNA and proteins of P2X7 are expressed, and the stimulation with
BzATP induced an increase in the [Ca2+]i and ethidium uptake, that
were prevented by the incubationwith oATP, suggesting that the recep-
tor might be functional. Furthermore, the stimulation of C6 cells with
BzATPwas responsible for the up-regulation of P2X7mRNA and protein
expression. Stimulation with BzATP also induced a four-fold increase in
cell migration [195]. Another study performed in same C6 cells as well
as human U-138MG cells, indicated that glioma cells were more resis-
tant to cell death and to the induction of caspase-3/7 activity upon stim-
ulationwith high extracellular concentrations of ATP (5mM) andBzATP
(100 μM) in comparison with non-cancerous organotypic hippocampal
slice cultures [211].
In highly invasive MDA-MB-435 s human breast cancer cells was,
P2X7 was found to be fully functional as activation of the receptor by
ATP gave rise to inward currents, increases in the [Ca2+]i and, to less de-
gree, ethidium uptake. The activation of the receptor by ATP also led to
the release of active cysteine cathepsins responsible for the proteolytic
degradation of the extracellular matrix and promoting cancer cell
invasiveness, with very mild effect on cell viability [132,163]. To notice,
in these studies, the pharmacological inhibition of P2X7 by both
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pression by the use of small interfering RNA signiﬁcantly inhibited basal
invasion in the absence of stimulation with an exogenous agonist. This
would favour the hypothesis of a basal activity of the receptor that
could be due to local and autocrine / paracrine release of ATP by cancer
cells. P2X7was also expressed in A549, PC-9 and H292 lung cancer cells
and its exogenous activation by ATP or BzATP, as well as the autocrine
release of ATP by cancer cells mediated by TGF-β1, also led to the in-
crease in cell invasiveness that was prevented by synthetic (A438079)
or natural (emodin) antagonists of the receptor [132,183,184]. Interest-
ingly, the migration of PC-9 cells was under the dependence of EGFR
receptors harbouring constitutively active mutations, and inhibition of
their activity with AG1478 and geﬁnitib inhibited both cell migration
and the expression of P2X7 proteins [184].
A study indicated that PC-3 human prostate cancer cells express
mRNA for P2X7 receptor, and while application of ATP was responsible
for the inhibition of cancer cell growth and viability, it was not
prevented by using the P2X7 antagonist KN-62 and was more likely
mediated by P2X5 [29]. In this study, it was not clear whether P2X7
was functional, since ATP failed to induce membrane permeabilisation,
assessed by the Lucifer yellow uptake assay. However, the ability of
the receptor to induce a characteristic ATP-mediated inward current
was not assessed and the involvement of P2X7 in other cancer proper-
ties was not speciﬁcally studied. In a recent study performed with
PC-3 cells, P2X7 was found to enhance the invasiveness of DU-145 in
PC-3 human prostate cancer cells [109]. These facts question on the
use of ATP-induced membrane permeabilisation as an indicator of
P2X7 functional expression.
5.1.1.3. Metabolic adaptation to tumour microenvironment. Hypoxic
episodes occurring in some areas of tumours would stabilise and acti-
vate the hypoxia-inducible factor-1α (HIF-1α) that would increase
the expression of P2X7. In both MCF-7 and MDA-MB-231 breast cancer
cells, hypoxia induced a HIF-1α-dependent increase of P2X7 expression
which in turn was responsible for sustaining cancer cell survival and in-
vasiveness through the activation of the ERK1/2 and Akt pathways and
the extracellular activity of MMP-2 andMMP-9 gelatinases [177]. In PC-
3 prostate cancer cells hypoxic episodes were associated with HIF-1α
stabilisation and translocation into the nucleus and to the increased
expression of P2X7 [212] which would also increase cancer cell inva-
siveness [109].
These results are in line with those obtained in the lab of Di Virgilio
showing that the overexpression of the full-length P2X7 was responsi-
ble for a metabolic adaptation of cells towards a glycolytic phenotype,
even in aerobic conditions [213]. This phenotype is well known as
being theWarburg effect and is associatedwith neoplastic development
and cancer aggressiveness [214]. Thismetabolic shift, was characterised
by the upregulation of HIF1α, the glucose transporter Glut-1, the glyco-
lytic enzymes glyceraldehydes 3-phosphate deshydrogenase G3PDH,
phosphofructokinase PFK pyruvate kinase PKM2 and pyruvate dehy-
drogenase kinase 1 PDHK1, along with the reduced expression of the
pyruvate deshydrogenase PDH, and allowed the cells to proliferate in
the absence of serum and in the very stringent environmental condi-
tions that could be found in developing tumours [213].
5.1.2. Anti-cancerous activities of P2X7 in cancer cells
5.1.2.1. Induction of apoptosis. In MCF-7 andMDA-MB-231 breast cancer
cells, P2X7 is proposed to negatively regulate cell proliferation and tu-
mour growth by inducing apoptosis and that the reduction of its expres-
sion by miR-150 which is upregulated in cancer tissues would reduce
cancer cell death and promote cancer cell and colony growth [179].
In the human A431 squamous cell carcinoma cell line P2X7 is found
to be expressed and, while its functionality was not clearly demonstrat-
ed, its stimulationwith high doses of ATP, ATPγS and BzATP reduced cell
numbers in vitro. These results, together with the ﬁnding that P2X7seemed to be expressed in apoptotic/necrotic foci of basal cell and squa-
mous cell biopsies, the authors of the study claimed that P2X7 was in-
volved in the ATP-mediated apoptosis in cancer cells [190]. Similarly,
P2X7 mRNA and protein are expressed in human HCT8 and Caco-2
colon adenocarcinoma cell lines and both ATP (1 mM) and BzATP
(100 μM) increased the [Ca2+]i. This was reduced in the presence of
oATP or KN-62. Stimulation of cancer cells with high concentrations of
ATP (2 mM) for 48 h reduced the cell viability as shown by measuring
the proportion of hypodiploid cells using ﬂow cytometry. This was at-
tributed to the induction of apoptosis in cancer cells. Pre-treatment of
cells with oATP inhibited this proapoptotic effect of ATP by about 50%,
which led the authors to conclude that P2X7 was involved in apoptosis
of intestinal epithelial cells but another P2 receptor might also contrib-
ute [198]. Yaguchi and collaborators also identiﬁed that high concentra-
tions of ATP reduced Caco-2 cancer cell growth through the inhibition of
PKC, but since they were unable to identify P2X7 mRNA expression,
they proposed that another unknown receptor was involved [215].
In A375 human melanoma cells, mRNA for P2X7 was detected, and
proteins were immunostained by using an antibody recognizing an
epitope in the C-terminus of the receptor. Even though, it remains
unknown if these cells express or not other splice variants, the one
detected was not truncated in the C-terminus and could correspond to
the full-length P2X7A. The stimulation of cells with hundreds of micro-
molar BzATP inducedmembrane permeabilisation to YO-PRO-1, the ac-
tivation of caspase-3/7 and resulted in a decrease in cell survival. While
the co-application of KN-62 only mildly reversed cell death, it was sug-
gested that P2X7 activation was pro-apoptotic and that its pharmaco-
logical targeting (activation) could provide a novel treatment of the
disease [30]. Following this hypothesis, they pursued with an in vivo
model in which athymic mice were subcutaneously inoculated with
A375 human melanoma cells. Mice were then treated with daily intra-
peritoneal injections of 1 mL D-PBS containing 50 mM ATP for 39 days.
The tumour volume and animal weight were measured over the course
of the experiment. The treatment with ATP was shown to decrease the
tumour volume by 50% in 7 weeks in treated mice, and prevented the
weight loss observed in untreated animals [216]. These results support-
ed the idea that ATP could be used as a treatment formelanoma, but the
exact mechanism and the receptors involved in the effects observed in
this experimental in vivo model were not demonstrated.
In a model of skin neoplasia induced by the administration of the
carcinogenetic and promoting agents, DMBA (7,12-dimethyl-benz(a)
anthracene) and TPA (12-O-tetradecanoylphorbol-13-acetate) respec-
tively, on the skin of FVB female mice, it was shown that the direct ap-
plication of BzATP reduced the proportion of living animals bearing
tumours, and the size of lesions [217]. This effect was attributed to the
induction of apoptosis in cancer cells stimulated by 100 μM BzATP.
No information was given on the expression of the different splice
variants and particularly of those being truncated in the C-terminus
that would be ineffective in inducing membrane permeabilisation. In
in vitro experiments, authors of this study showed that the application
of 100 μM BzATP increased the [Ca2+]i, induced membrane
permeabilisation to ethidium and induced apoptosis in normal
keratinocytes fromwild-type mice, while it failed to induce ATP in nor-
mal keratinocytes coming from P2X7−/− mice. In chimio-induced
cancer tissues, it appeared that the expression of the full-length P2X7,
monitored by both western blotting and immunohistochemistry, was
decreased compared to the normal skin. These results prompted the
authors to conclude the diminished pro-apoptotic effect of BzATP in
cancer keratinocytewas due to a lower expression of P2X7 as compared
to normal keratinocyte. They also proposed that the activation of
apoptosis in cancer cells through the activation of P2X7 with BzATP
could represent a novel chemotherapeutic growth-preventingmodality
for skin cancers in vivo [217]. While this study is of sure interest it did
not consider the participation of other P2 receptors in vivo, and the
risk and side effects that could be triggered by such treatments. Further-
more, the P2X7 receptor is depicted as a pro-apoptotic receptor being
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ulating the cells with high doses of BzATP. However, such pharmacolog-
ical and prolonged stimulations of P2X7 can trigger cellular responses
that are not the same than those activated by the receptor under basal
conditions. As such it is possible that such experiments do not allow
the determination of the real role played by P2X7 in cancer biology.
While the release of low concentrations of ATP (in the 10 nM range),
mediated by basal activity of P2X7 in B16 mouse melanoma cells, was
indirectly inducing an increase in cancer cell proliferation, high concen-
trations of ATP (in the 3mM range) thus possibly directly activating the
receptor and inducingmembrane permeabilisation had opposite effects
[192]. Therefore the level of ATP released, aswell as themode and time-
scale of the activation of P2X7, might result in striking different effects.
Further supporting this idea, it has been proposed that high concentra-
tions of ATP, which could be released by dying cancer cells in necrotic
areas of tumours, could directly kill adjacent tumour cells via P2X7.
Therefore, maintaining high concentrations of ATP by inhibiting the
ectonucleotidase CD39 would have an anti-tumour effect [218]. While
such a hypothesis is tempting, it is hard to understand how very aggres-
sive tumours, showing multiple necrotic foci, still continue to naturally
grow and to metastasise.
In a recent study performed inmouseMCA38 colon adenocarcinoma
cells and in mouse B16 melanoma cells, the P2X7a variant (but not the
P2X7k variant) is expressed (mRNA) and the stimulation of cells with
high doses of ATP (up to 5mM) and to BzATP (up to 2mM)was respon-
sible for ethidium uptake and for a reduction in cell viability and in
clonogenicity. The proposed mechanism is a decrease in the intracellu-
lar content of ATP and a deregulation of the PI3K/Akt and AMPK-
PRAS40-mTOR signalling pathways that perturb the balance between
cell growth and autophagy [193].
5.1.2.2. Inhibition of cancer cell proliferation and tumour growth. In C6 rat
glioma cells, both the pharmacological (BBG) and themolecular extinc-
tion (siRNA) were found to have growth promoting effect in vitro and
in vivo. These effects were not due to a signiﬁcant reduction in
caspase-3 induction in cancer cells, but rather as a consequence of the
over-expression of EGFR, HIF1-α, VEGF and P2Y2 [196]. In GL261
mouse glioma cells, high concentrations of ATP (5 mM) and BzATP
(up to 3 mM) induced the uptake of propidium iodide and a rapid
increase in extracellular LDH activity, external exposure of
phosphatidylserine and a reduction of cell survival measured by MTT
cell viability assay, which were claimed to be mediated by P2X7.
These effects were not observed in P2X7-expressing rat C6 or human
U138 and U87 glioma cells [197].
The effect of P2X7 agonists, ATP and BzATP, in combination or not
with irradiation (2Gy) on cell death was studied in human U-138MG,
U-251MG and M059J glioma cells. All the three cell lines expressed
P2X7 proteins, but the radiosensitive M059J glioma cells signiﬁcantly
expressed higher levels of proteins, and showed a higher ethidium up-
take upon ATP (5 mM) stimulation, both in the absence or presence of
irradiations, than in the two other cell lines. P2X7 agonists produced
cell death in the radiosensitiveM059J cell line, but the radioresistant gli-
oma cell lines U-138MG and U-251MG presented resistance to death
when treated with either ATP or BzATP [194]. While authors claimed a
relevance of P2X7 activation for increasing glioma radiosensitivity,
more experiments are necessary to really understand the roles of
P2X7 in the acquisition of resistances to therapeutic strategies.
5.1.2.3. Inhibition of cancer cell migration. In a recent study, it is shown
that P2X7 is expressed in human MDA-MB-231 breast cancer cells,
however its stimulation by the non-hydrolysable analogue ATPγS re-
duces cancer cell growth, migration, and inhibits the growth of
orthotopic xenograft tumours due to the injection of same human
cells in the mammary fat pad of nude mice [219]. In this same study,
while the activity of P2X7 was not clearly demonstrated, it was pro-
posed that its persistent stimulation with ATPγS reduced mousePy8119 breast cancer cell migration in vitro and tumour growth in a
model of intratibial injection of cells in C57bl/6 mice [219].
It is widely accepted that the anti-proliferative or pro-apoptotic ef-
fect resulting from exogenous stimulation of P2X7 in some cell types
are associated with the membrane permeabilisation property. It can
be postulated that, in some cancer cells P2X7 is fully functional as an
ion channel but not inducing membrane permeabilisation, because of
the expression of a C-terminus truncated variant or due to the molecu-
lar uncoupling to pore forming channels such as pannexin-1. In such
cases, P2X7 would control other cellular properties such as cancer cell
invasiveness. If this hypothesis can be veriﬁed, it can be proposed that,
selective induction of membrane permeabilisation in cancer cells
might represent a new strategy to treat cancers, probably more speciﬁc
than the pharmacological targeting of P2X7.
5.2. P2X7 receptors in tumour-associated immune cells
Tumours are inﬁltrated with different subsets of immune cells and
some tumours originate from a chronic inﬂammatory environment,
and thus there is a well-orchestrated functional interaction among in-
ﬂammatory inﬁltrates and the tumour [220,221]. P2X7 is highly
expressed and controls the function of different immune cells such as
monocytes, macrophages, dendritic cells and lymphocytes [222–224].
As detailed in the previous section, tumour microenvironment present
high levels of extracellular ATP and therefore activation of the P2X7 is
likely to occur in tumours inﬁltrated by immune cells. However, P2X7
function in tumour-associated immune cells will elicit a pro-
tumorigenic response contributing to tumour growth and progression
by inducing the production of different pro-tumorigenic factors such
as extracellular matrix-degrading enzymes and other bioactive mole-
cules such as VEGF or prostaglandins [225–228]. This is mainly due to
the fact that tumour-associatedmacrophages present anM2 alternative
activated phenotype associated with tissue remodelling and the resolu-
tion of the inﬂammation, where P2X7 function uncouples from pro-
inﬂammatory cytokines production [175,229,230]. This event plays a
pivotal role in the lack of immunity against tumours and the failure to
elicit a robust immune response to remove cancer cells. Tumour-
associated macrophages would be immunosuppressive and therefore
would prevent the attack of tumour cells by natural killer and T-cells
[230]. In this context, immunotherapy treatments against tumours
aim to elicit a robust pro-inﬂammatory response that will prime innate
dendritic cells andmacrophages towardsM1 inﬂammatory phenotypes
for efﬁcient tumour-associated antigen presentation to lymphocytes
[231,232]. In this regard, anticancer treatments, such as radiotherapy
or some chemotherapeutic agents, besides to induce direct cytotoxic ef-
fects on cancer cells, they also mediate immunogenic cell death and
therefore elicit an IFNγ-mediated immune response required for the ef-
ﬁcacy of these treatments [233,234]. In the tumour environment dying
tumour cells succumbing to chemotherapy further increased the activa-
tion of P2X7 in macrophages and dendritic cells via the release of ATP.
This release of ATP in conjunction with Toll-like receptor (TLR) engage-
mentwith other DAMP signals, such as theHMGB1, are essential to elic-
it a proper anti-cancer immunity [235,236]. In macrophages and
dendritic cells, the activation of these pathways converges in the assem-
bly of the inﬂammasome, a central innate immune sensor for
pathogens-associated molecular patterns (PAMPs) and/or DAMPs [76,
237,238]. The NLRP3 inﬂammasome activated via P2X7, has been de-
scribed as being responsible for eliciting CD8+ T-cell mediated cancer
eradication following anticancer treatments [51,236]. However, NLRP3
and other inﬂammasomes, including NLRC4 and NLRP6, have been
also implicated in tumorigenesis [239]. Therefore in the context of can-
cer, P2X7 activation during tumorigenesiswill play different roles in dif-
ferent types of cancers, being beneﬁcial in certain circumstances and
injurious in others. The use of speciﬁc drug-like P2X7 antagonists
targeting immune cells could be detrimental in the ﬁrst steps of cancer
development by inducing an immune tolerogenic response. In contrast,
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P2X7 could decrease the tumour-promoting function of tumour-
associated macrophages [44].
6. Conclusions and perspective on future research direction
From the 1980s, the importance of extracellular adenine nucleotides
was demonstrated in carcinogenesis. At that time it was demonstrated
that the application of exogenous ATP or ADP had anti-cancerous
properties through the inhibition of cancer cell growth, and ATP or
BzATP were even proposed as treatment modalities in vivo in animal
models and in humans [45–49]. This hypothesis was further supported
until recently [50]. However, while treatmentswith ATPhad very strong
cytotoxic effects on cancer cells from several tumours, it also appeared
that in some other occasions it could have pro-cancerous activities
[25]. Besides, treatments with ATP or analogs could initiate nociceptive
pathways through the activation of P2X3 receptors on sensory nerves.
These intriguing results prompted researchers to study in details the
activity and participation of the purinergic signalling, and purinergic
receptors, in carcinogenesis and in the progression of cancers, as well
as the release mode and concentrations of nucleotides in the tumour
site [26]. Results obtained are of primary importance as they could
lead to the formulation of novel therapeutic strategies and to the
repurposing of purinergic receptor antagonists developed for the
treatment of other pathologies in the cancer treatment. Among all P2
receptors studied in the context of cancer initiation and progression,
the P2X7 receptor seemed to attract the most of interest and also
probably generated the most of controversy on its expression, activity
and postulated role. With the exception of some experiments, among
which those performed on uterine cancers, most of the studies
performed in cancer biopsies and cancer cells indicated the over-
expression of P2X7. Multiple studies appeared contradictory in their
results when assessing the possible involvement of P2X7 in oncogenic
processes. However, a careful analysis of the experiments conducted
should help in determining such discrepancies, in proposing new
hypotheses and important aspects of P2X7 properties that will have to
be examined in the future studies. A critical point will be to clearlyA Endogenous ATP
ATP Pore
B
Ca2+, Na+
K+
basal activities
Cancer cell
metabolism Migration / invasion
P2X7
Proliferation
Tumour growth and metastases
Fig. 3. Schematic representation of the participation of P2X7 receptor in epithelial cancer cell b
membrane diffusion or vesicular release is responsible for a pericellular halo that activates P2X
cell metabolism and promoting cell proliferation, migration and invasiveness. These properties
enous stimulation with high concentrations of ATP or BzATP would tend to overactivate P2X7 r
and to the membrane permeabilization. This would induce cancer cell apoptosis.analyse, in cancer cells, the presence and intensity of all the functional
properties classically attributed to P2X7 (ATP-induced current, intracel-
lular Ca2+ increase, membrane permeabilisation, etc.) as they might be
associated with different biological functions. It is also obvious that the
cells expressing P2X7 in a tumour (cancer cells versus non-cancer cells)
are important to consider as they might be associated with either
pro-cancerous or anti-cancerous immune properties. Not only the
cells are important, but the step of the carcinogenesis or grade of the
tumour should be considered. P2X7 activation during tumorigenesis
could play different roles in different types of cancers, being beneﬁcial
in certain circumstances, and injurious in others. The use of speciﬁc
drug-like P2X7 antagonists targeting immune cells could be detrimental
in the ﬁrst steps of cancer development by inducing an immune
tolerogenic response. In contrast, when the primary tumour is
established, pharmacological blockage of P2X7 could result at least in
the decrease of the tumour-promoting function of tumour-associated
macrophages. It could also reduce the pro-cancerous effect of P2X7
function in cancer cells. Future studies will have to determine the
pattern of expression of the different P2X7 splice variants, not only
the expression of the full-length P2X7A, in both non-cancerous and
cancerous cells, as they could be responsible for various or even oppo-
site regulations of biological functions. Such an analysis was recently
initiated with a study performed in osteosarcoma samples and
cells [240]. Authors showed that both P2X7A and P2X7B variants
were expressed in most osteosarcoma samples analysed and that they
were responsible for differential effects on cell growth and matrix
mineralisation.
From this overview of the literature, it can be postulated that basal
activity of P2X7 in cancer cells from an established tumour could be
pro-cancerous [146,208,210], while the exogenous stimulation of P2X7
[50], or the endogenous stimulation following anticancer treatment and
cell death [51], with high concentrations of extracellular ATP could be
anti-cancerous (Fig. 3). However, it is now understood that the exoge-
nous stimulation of cells with (high) concentrations of hydrolysable or
non-hydrolysable agonists, for a long period of time, even if giving
interesting results in vitro, might not reﬂect what is really happening in
tumours in vivo. As such, the results obtained might be consideredExogenous ATP / BzATP
High concentrations
Pore
Membrane
permeabilization
High [Ca2+]i
P2X7
Apoptosis
Ca2+, Na+
K+
Cancer cell death
iology. (A) In epithelial cancer cells, the autocrine/paracrine release of ATP, through trans-
7 into a basal mode activity, with no or weak membrane permeabilization, thus increasing
would promote tumour growth and progression towards metastatic steps. (B) The exog-
eceptors into a cytolytic mode, due to the high increase of intracellular Ca2+ concentration
2600 S. Roger et al. / Biochimica et Biophysica Acta 1848 (2015) 2584–2602respectfullywith these limitations. In linewith this aspect, it appears that
P2X7 could have a basal activity, due the autocrine / paracrine release of
ATP in concentrations that are supposed to be much lower than those
used in vitro to stimulate the receptor.
Furthermore, it can also be postulated that P2X7 expression and
functionality in cancer cells, together with the endogenous ATP in the
tumour, represent key parameters for the selection of cancer cells
with an aggressive phenotype. This was formulated as being the “Run
or die hypothesis”: the increase of the extracellular ATP concentration
in the tumour could represent a stressful selective pressure for from
which many cancer cells would die while some other, that do not
undergo apoptosis, that are the most invasive, would be selected [44].
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